Archives     Advertise     Editorial Calendar      Advertiser Index     Subscribe     Contact Us    

Vibativ® Effectively Helps Treat Secondary Bacterial Infections In COVID-19 Patients


Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today released a series of case reports describing the effectiveness of Vibativ® (telavancin) in treating secondary bacterial infections in COVID-19 patients - particularly those with other significant health problems, such as obesity, diabetes and heart disease.

The dossier of patient case studies outlines five real-world instances where Vibativ effectively and safely treated hospital-acquired and ventilator-associated bacterial pneumonia in COVID-19 patients. These types of pneumonia result from serious staph infections, such as methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA).

"We have seen that the timely and appropriate use of potent antibiotics such as Vibativ can improve patient outcomes and even be life-saving," said A.J. Kazimi, chief executive officer of Cumberland Pharmaceuticals. "In patients with underlying conditions, mortality risk from COVID and bacterial pneumonia can be especially high. Cumberland is proud to offer an injectable antibiotic that can provide a rapid resolution to the bacterial infection."

Dr. Joseph Reilly, a clinical pharmacist specialist for infectious disease and critical care at AtlantiCare Regional Medical Center in Pomona, N.J., provided two COVID-19 patient cases for the dossier. Both patients had diabetes, heart disease and other underlying health conditions. One patient presented with MSSA hospital-acquired bacterial pneumonia (HABP) and the other with MRSA ventilator-associated bacterial pneumonia (VABP).

"In these patients, bacterial pneumonia developed and likely contributed to their failure to improve clinically," said Dr. Reilly. "Within 48 hours of switching antibiotic therapy to telavancin, blood cultures were clear of MSSA and MRSA. These cases illustrate the clear need for an antibiotic like telavancin, which rapidly and effectively eradicates secondary bacterial pneumonia that can develop in patients with COVID."

Cumberland's Vibativ (telavancin) has been used across the country to help COVID-19 patients who develop secondary bacterial infections in their lungs. The five case studies in Cumberland's dossier illustrate that once-daily dosing of telavancin can effectively and safely treat HABP or VABP due to Gram-positive infection among COVID-19 patients.

Vibativ is a patented, FDA-approved injectable anti-infective for the treatment of certain serious bacterial infections including HABP and VABP that can result from COVID-19, flu and other infections. It is also approved for complicated skin and skin structure infections. It addresses a range of Gram-positive bacterial pathogens, including those that are considered difficult-to-treat and multidrug-resistant.

In March 2020, Cumberland announced an initiative to expand the availability of Vibativ to treat HABP and VABP in COVID patients across the U.S., which included the opportunity for healthcare facilities to make special financial arrangements to help ensure supply. The company also sponsored a national program with infectious disease experts to provide information on the management of complicated respiratory infections resulting from COVID-19.


Related Articles:

Recent Articles

AACR Establishes New Cancer Evolution Working Group

The American Association for Cancer Research (AACR) announced the formation of its seventh and newest scientific working group, which will be dedicated to supporting cancer evolution research.

Read More

Global Dementia Cases Forecasted To Triple By 2050

New analysis shows a decrease in prevalence due to education countered by increase due to heart health risk factors

Read More

Blackburn, Feinstein Introduce Bill to Protect Access to Breast Cancer Screenings

U.S. Senators Marsha Blackburn (R-Tenn.) and Dianne Feinstein (D-Calif.) today introduced the Protecting Access to Lifesaving Screenings (PALS) Act of 2021, a bill to preserve coverage for routine breast cancer screening for women beginning at age 40.

Read More


The company's 2020 sustainability report highlights its commitment to environmental, social and governance (ESG) activities

Read More

Mobile Mentor Named Winner of Microsoft's 2021 Partner of the Year for Modern Endpoint Management

Mobile Mentor announced they have been awarded the 2021 Global Partner of the Year Award for Modern Endpoint Management.

Read More

Alzheimer's Association Welcomes CMS Announcement of National Coverage Determination Analysis on Treatment for Alzheimer's Disease

On behalf of all those living with Alzheimer's disease, their caregivers, and their families, we appreciate the Centers for Medicare & Medicaid Services (CMS) thoughtful consideration on coverage considerations for monoclonal antibodies targeting amyloid for the treatment of Alzheimer's disease, including aducanumab, which was recently approved by the Food and Drug Administration (FDA).

Read More

HCTec Acquires Talon Healthy IT Services

Healthcare IT firm adds industry-leading help desk service company to portfolio of solutions

Read More

The Seven Steps of Revenue Cycle for a Healthcare Practice

Revenue cycle management tracks patient revenue from the initial encounter with the healthcare system to payment of balance. Getting the seven steps of revenue cycle right helps providers avoid missteps that are costly to the bottom line.

Read More

Expanding Evidence-Based Care for Dementia

The Alzheimer's Association is on a mission to ensure care professionals have access to evidence-based training to ensure those with dementia receive quality care across all settings.

Read More

A Natural Leader

Nashville physician Dr. Ryan Mire to head nation's largest medical-specialty society.

Read More

Email Print



Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: